AYOXXA Biosystems GmbH
- Land: Deutschland
Nachricht vom 07.01.2019 | 16:00
AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
DGAP-News: AYOXXA Biosystems GmbH / Key word(s): Agreement
AYOXXA signs research agreement in the field of ophthalmology
Cologne, Germany, January 07, 2019, 7:00am PST - AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced that it has signed a research agreement with one of the leading pharmaceutical companies for the development of a series of low volume, high sensitivity multiplex protein assays intend to validate protein biomarkers in the field of ophthalmology. Financial details were not disclosed.
The collaboration announced today is the initial phase of a multi-study plan between AYOXXA and its pharmaceutical partner to collaborate in the field of ophthalmology. In a first step, AYOXXA will leverage its proprietary multiplex immunoassay platform to develop specific in vitro assays in collaboration with the partner's research and development team. The assays will be used in clinical studies with multiple patient cohorts to identify and validate molecular biomarkers to supporting the company's drug development efforts in ophthalmology.
Specimens used in ophthalmology are scarce and only limited sample volumes are available from clinical interventions or animal models. Also, the high viscosity of matrices like e.g. vitreous fluid often impedes the precise quantification of certain biomarkers.
AYOXXA's proprietary system LUNARISTM is specifically designed for multiplex protein analysis for biomarker identification and validation in highly precious and scarce samples. The innovative BioChip format and the planar geometry allow LUNARISTM assays to be performed with sample volumes as low as 3µL - which represents only 1/10 of the volume required by comparable multiplex technologies. LUNARISTM can be readily integrated into any laboratory routine and is optimized to provide an easy-to-use, standardized workflow from sample to result. It combines the familiarity of standard immunoassay workflow with unmatched capability for low sample volume, scalability for low- to high-throughput applications and market leading data quality. The system comprises a dedicated LUNARISTM reader and best-in-class LUNARISTM software for image-based analysis with a 100% read-out.
LUNARISTM kits follow a classical sandwich immunoassay principle with fluorescence readout. The panels and assays are painstakingly optimized using the best quality antibody-pairs to ensure the highest assay sensitivity and specificity with minimal cross-reactivity in a multiplex format.
For more information on the LUNARISTM Kit portfolio, please visit AYOXXA's website.
AYOXXA Biosystems GmbH is an international life science company based in Cologne (Germany) with offices in Boston, MA (USA) and Singapore. AYOXXA enables its customers and partners to utilize its reliable and optimized platform technology to fuel breakthroughs in all areas of life science research and to enhance success in translational science.
With LUNARISTM, its proprietary innovative beads-on-a-chip multiplexing platform for advanced protein analysis, the Company is paving the way for translating knowledge generated in a laboratory environment through clinical studies in support of basic biology and drug development. With its advantages in terms of quality, flexibility, robustness and efficiency, LUNARISTM enables fully scalable quantitative validation of biomarkers in minute amounts of biological samples. AYOXXA is commercializing a growing portfolio of standardized ready-to-use biomarker analysis assays, with a focus on the biology of inflammation and immune response.
For more information, please visit www.ayoxxa.com
Follow AYOXXA on LinkedIn.
LUNARISTM products are intended "for research use only" and may not be used in diagnostic procedures.
AYOXXA unterzeichnet Forschungsvereinbarung mi ...
AYOXXA signs research agreement in the field o ...
AYOXXA launches LUNARIS(TM) Human & Mouse 6-Pl ...
AYOXXA launches LUNARIS(TM) Human 12-Plex Th17 ...
AYOXXA @ BIO-Europe Spring(R) 2018 - 12th Inte ...
Der AKTIONÄR News
23. Januar 14:23 RWE: Geldregen möglich, Aktie springt an – die Hintergründe!
23. Januar 14:09 Deutsche Post: Jetzt ein Kauf!
23. Januar 13:59 IBM übertrifft Erwartungen – Aktie steigt
23. Januar 11:55 Deutsche Bank-Aktie: Das ist wirklich erstaunlich
News im Fokus
Deutsche Börse AG: Deutsche Börse AG rechnet mit deutlicher Überschreitung der Gewinnprognose für 2018
22. Januar 2019, 20:25
Fourth Quarter and Full Year 2018 Earnings Call
13. Februar 2019
Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy
22. Januar 2019